| Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+T cells | 
                                    
                                    
                                        | Author | 
                                        Jiang, XY; Lin, J; Shangguan, CF; Wang, XY; Xiang, B; Chen, J; Guo, HZ; Zhang, W; Zhang, J; Shi, Y; Zhu, J; Yang, H | 
                                    
                                    
                                        | Journal | 
                                        JOURNAL OF CLINICAL INVESTIGATION | 
                                    
                                    
                                        | Pub Year | 
                                        2023 | 
                                    
                                    
                                        | Type | 
                                        Article | 
                                    
                                    
                                        
                                            
                                                | Abstract | 
                                                Antitumor activity of CD8+ T cells is potentially restrained by a variety of negative regulatory pathways that are triggered in the tumor microenvironment, yet, the exact mechanisms remain incompletely defined. Here, we report that intrinsic RIG-I in CD8+ T cells represents such a factor, as evidenced by observations that the tumor-restricting effect of endogenous or adoptively transferred CD8+ T cells was enhanced by intrinsic Rig-I deficiency or inhibition, with the increased accumulation, survival, and cytotoxicity of tumor-infiltrating CD8+ T cells. Mechanistically, T cell activation-induced RIG-I upregulation restrained STAT5 activation via competitive sequestering of HSP90. In accordance with this, the frequency of RIG-I+ tumor-infiltrating CD8+ T cells in human colon cancer positively correlated with attenuated survival and effector signatures of CD8+ T cells as well as poor prognosis. Collectively, these results implicate RIG-I as a potentially druggable factor for improving CD8+ T cell-based tumor immunotherapy. | 
                                            
                                        
                                    
                                    
                                        
                                            
                                                | Issue | 
                                                133 | 
                                            
                                        
                                    
                                    
                                        
                                            
                                                | Volume | 
                                                133 | 
                                            
                                        
                                    
                                    
                                        
                                            
                                                | SCI | 
                                                15.9 |